How do you treat at the speed of cancer?

The Answers AreIn Our Blood

Guardant360® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors

left hand right hand
Latest clinical data.*
View the evidence
New England Journal Of Medicine
Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Clinical Cancer Research
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer.
JAMA Oncology
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Clinical Lung Cancer
Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Journal of Clinical Oncology
Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis.

*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.